Key facts
- Notable investors include Evolution VC Partners, Spring Mountain Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Valorum Biologics
- ·The full record, as it builds
Funding rounds
No funding rounds for Valorum Biologics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Valorum Biologics
Developer of a biosimilar pipeline designed to expand patient access to biologic drugs for serious diseases. The company offers clinically proven assets with a focus on ophthalmology and oncology, enabling underserved patient populations to benefit from high-value, first-to-market therapies at a lower cost.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2021
- Website
- valorum.bio/
- Ownership
- Privately Held (backing)
Valorum Biologics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Valorum Biologics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Valorum Biologics in its N-PORT filings yet. We sweep new filings monthly.